HotSpot Therapeutics Shares Phase 1 Data on CBL-B Inhibitor HST-1011 at 2024 SITC Meeting

BOSTON, Nov. 7, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the development of oral, small molecule therapies targeting regulatory sites on proteins known as "natural hotspots," today announced it will present new Phase 1 clinical biomarker data for HST-1011. This investigative oral inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B) will be discussed in a poster presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

"These emerging biomarker data from our Phase 1 clinical study of HST-1011 strongly support the biological activity and therapeutic potential of CBL-B inhibition. Treatment with HST-1011 has shown an increase in immune activation, as indicated by both peripheral blood and tumor gene expression," said Alison O'Neill, M.D., Chief Medical Officer of HotSpot Therapeutics. "While the data are preliminary and from a small patient cohort, baseline immune signature analyses suggest the possibility of predicting clinical response. Overall, these insights encourage further investigation of biomarkers as HST-1011 progresses in clinical development."

The presentation highlights additional clinical biomarker data from the ongoing Phase 1 monotherapy dose-escalation study of HST-1011:
- A gene response signature derived from HST-1011 showed a consistent dose-dependent increase in patients' peripheral blood, with those showing clinical benefit exhibiting higher signature expression in on-treatment biopsies.
- Preliminary next-generation sequencing data of T- and B-cell receptors indicated that HST-1011 affected both immune cell populations, with changes in several metrics linked to clinical benefit.
- At baseline, patients who responded positively to HST-1011 treatment had higher tumor-infiltrating lymphocyte expression and a higher immune signature score, suggesting potential for predicting clinical benefit.

About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of allosteric drugs that target naturally occurring pockets on proteins termed "natural hotspots." These pockets play a crucial role in controlling protein function and present significant potential for new drug discovery. The Company's proprietary Smart Allostery™ platform integrates computational methods and AI-driven data mining of extensive datasets to identify hotspots and use tailored pharmacology toolkits and bespoke chemistry to quickly discover novel hotspot-targeted small molecules. Using this approach, HotSpot is developing a diverse pipeline of novel allosteric therapies for cancer and autoimmune diseases.